Announced Wed, 8 Apr · 18:25 IST
Clarification on identical standalone and consolidated Q2 FY26 results
Regulatory & Legal View source PDF
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹552.00
prior close
₹552.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.0+0.8+0.1+4.0+3.3+7.1+6.9+6.0+10.0+16.3+26.7+15.1+10.2
Up moveDown movePending
AI summary
Lincoln Pharmaceuticals responded to NSE's query on its Q2 FY26 (ended Sep 30, 2025) results, where NSE noted that standalone and consolidated P&L figures were identical, flagging a possible format issue. The company explained that its only subsidiary, an LLP, had no financial transactions during the quarter, so the consolidated results mirror the standalone results. The original results were published on Nov 13, 2025.
Likely market impact
Minor administrative clarification with no financial or operational impact; routine compliance matter resolved.